Eiger biopharmaceuticals, inc. (EIGR)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating expenses:
Research and development

51,791

37,091

29,519

33,014

8,117

644

426

13,314

General and administrative

17,113

13,956

12,001

13,106

4,855

872

526

2,631

Total operating expenses

68,904

51,047

41,520

46,120

12,972

1,516

952

15,945

Loss from operations

-68,904

-51,047

-41,520

-46,120

-12,972

-1,516

-952

-15,945

Interest expense

3,406

2,329

1,524

690

350

-

-

108

Interest income

2,073

997

410

97

-

-

-

35

Other income (expense), net

-15

-12

186

-374

-

-

-

147

Consolidated net loss

-

-

-

-

-

-

-

-15,871

Net loss attributable to non-controlling interest

-

-

-

-

-

-

-

-154

Net loss

-70,252

-52,391

-42,448

-47,087

-13,322

-1,516

-

-15,717

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

343

Change in fair value of non-controlling interest

-

-

-

-

-

-

-

-154

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-16,214

Consolidated net loss

-

-

-

-

-

-

-

-15,871

Unrealized (loss) gain on investments

-

-

-

-

-

-

-

9

Net loss and comprehensive loss

-

-

-

-

-

-

-952

-

Comprehensive loss

-

-

-

-

-

-

-

-15,862

Net loss per common share, basic and diluted

-3.08

-3.84

-4.86

-7.84

-62.19

-7.82

-4.92

-19.74

Weighted-average common shares outstanding, basic and diluted

22,785

13,634

8,727

6,007

214

193

193

821